Translational Applications of Tissue Engineering in Cardiovascular Medicine.
Cardiovascular diseases are the leading cause of global deaths. The current paradigm in medicine seeks novel approaches for the treatment of progressive or end-stage diseases. The organ transplantation option is limited in availability, and unfortunately, a significant number of patients are lost while waiting for donor organs. Animal studies have shown that upon myocardial infarction, it is possible to stop adverse remodeling in its tracks and reverse with tissue engineering methods. Regaining the myocardium function and avoiding further deterioration towards heart failure can benefit millions of people with a significantly lesser burden on healthcare systems worldwide. The advent of induced pluripotent stem cells brings the unique advantage of testing candidate drug molecules on organ-on-chip systems, which mimics human heart in vitro. Biomimetic three-dimensional constructs that contain disease-specific or normal cardiomyocytes derived from human induced pluripotent stem cells are a useful tool for screening drug molecules and studying dosage, mode of action and cardio-toxicity. Tissue engineering approach aims to develop the treatments for heart valve deficiency, ischemic heart disease and a wide range of vascular diseases. Translational research seeks to improve the patient's quality of life, progressing towards developing cures, rather than treatments. To this end, researchers are working on tissue engineered heart valves, blood vessels, cardiac patches, and injectable biomaterials, hence developing new ways for engineering bio-artificial organs or tissue parts that the body will adopt as its own. In this review, we summarize translational methods for cardiovascular tissue engineering and present useful tables on pre-clinical and clinical applications.
Arin
A
Dogan
A Eser
AE
Elcin
Ankara University Faculty of Science, Tissue Engineering, Biomaterials & Nanobiotechnology Laboratory, Degol Caddesi, Tandogan 06100 Ankara, Turkey.
Y Murat
YM
Elcin
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology; D012038:Regeneration / Q000187:drug effects / Q000502:physiology*; D023822:Tissue Engineering / Q000379:methods* / Q000639:trends; D054457:Tissue Scaffolds / Q000639:trends; D057170:Translational Research, Biomedical / Q000379:methods* / Q000639:trends
D002317:Cardiovascular Agents
Cardiovascular tissue engineering; angiogenesis; cardiac patch; decellularization; drug testing; extracellular matrix; heart valve tissue engineering; injectable biomaterials; myocardial
infarction; vascular tissue engineering